Beyond Air (NASDAQ:XAIR) Earns Buy Rating from D. Boral Capital

Beyond Air (NASDAQ:XAIR)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $10.00 price target on the stock.

Several other brokerages have also recently issued reports on XAIR. Rodman & Renshaw initiated coverage on Beyond Air in a research report on Tuesday, January 20th. They set a “buy” rating on the stock. Wall Street Zen raised Beyond Air to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of Beyond Air in a report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Beyond Air has a consensus rating of “Hold” and a consensus target price of $10.00.

Beyond Air Stock Performance

Shares of XAIR traded down $0.02 during mid-day trading on Tuesday, reaching $0.84. 29,507 shares of the company’s stock traded hands, compared to its average volume of 9,930,755. The company has a debt-to-equity ratio of 2.65, a quick ratio of 4.77 and a current ratio of 5.12. The business’s 50-day moving average price is $1.14 and its 200-day moving average price is $1.61. The stock has a market capitalization of $8.83 million, a P/E ratio of -0.15 and a beta of 0.41. Beyond Air has a 12 month low of $0.67 and a 12 month high of $6.44.

Beyond Air (NASDAQ:XAIR) last issued its quarterly earnings results on Friday, February 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.31). Beyond Air had a negative net margin of 447.75% and a negative return on equity of 268.82%. The business had revenue of $2.19 million for the quarter, compared to analyst estimates of $2.15 million. Equities analysts predict that Beyond Air will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Beyond Air

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Beyond Air by 57.5% during the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock worth $49,000 after purchasing an additional 24,695 shares during the last quarter. Alpine Global Management LLC acquired a new stake in shares of Beyond Air in the 3rd quarter valued at $25,000. Alyeska Investment Group L.P. acquired a new stake in shares of Beyond Air in the 3rd quarter valued at $1,753,000. Virtu Financial LLC acquired a new position in Beyond Air during the third quarter worth $48,000. Finally, Osaic Holdings Inc. raised its holdings in Beyond Air by 26.4% during the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after buying an additional 34,000 shares in the last quarter. 31.50% of the stock is currently owned by hedge funds and other institutional investors.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.